Available Treatment Options for Patients with Relapsed Multiple Myeloma
Ashley Rosko, MD, presents the case of a 72-year-old woman with relapsed multiple myeloma for discussion.
EP: 1.Personalized Therapy Options Are on the Horizon in Multiple Myeloma
EP: 2.Treatment Approaches for Patients With Newly-Diagnosed Multiple Myeloma (NDMM)
EP: 3.Transplant Eligibility in Patients With NDMM
EP: 4.Treatment Considerations for Patients with High-Risk NDMM
EP: 5.First-Line Treatment Options for Patients With Transplant-Ineligible NDMM
EP: 6.Data Updates on the Treatment of Transplant-Ineligible NDMM From the MAIA Trial
EP: 7.Selecting Between Doublet and Triplet Regimens for Patients With Transplant-Ineligible NDMM
Now Viewing
EP: 8.Available Treatment Options for Patients with Relapsed Multiple Myeloma
EP: 9.Updates on Bispecific T-Cell Engager (BiTE) Antibodies in Relapsed Multiple Myeloma
EP: 10.Other Bispecific Antibodies Under Investigation for Treatment of Relapsed Multiple Myeloma
EP: 11.CAR T-Cell Therapy vs Bispecific Antibodies for Patients With Refractory Multiple Myeloma
EP: 12.Unmet Needs and Future Perspectives in Newly-Diagnosed and Relapsed Multiple Myeloma
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
![We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fa0c5316b5733cfe8ccceb396476faf0cea2f2e46-320x410.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
